NYSE:LHHealthcare
Labcorp Holdings (LH) Launches FDA-Cleared Alzheimer's Diagnostic Blood Test Nationwide
Labcorp Holdings (LH) experienced a 10% price increase in the past month, which aligns with its recent strategic advancements including the launch of Lumipulse® pTau-217/Beta Amyloid 42 Ratio, marking a significant enhancement in Alzheimer’s diagnostics. This breakthrough likely bolstered investor confidence, dovetailing with broader market trends that saw the Dow Jones reach new highs. Meanwhile, despite a generally mixed performance among major indices, the company's second-quarter earnings...